AbbVie Submits Marketing Authorization Application to EMA fo

AbbVie today announced it has submitted a marketing authorization application to the European Medicines Agency for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.

Related Keywords

Iceland , Norway , Liechtenstein , Lichtenstein , Danielle Ellis , Committee For Medicinal Products Human , European Union , European Medicines Agency , International Classification Of Headache Disorders , From Abbviejul , Michael Gold , International Classification , Headache Disorders , Medicinal Products , Human Use , Northern Ireland , Migraine , Hronic , Clinical Trial , Constipation , Disability , Efficacy , Headache , Nausea , Neurological Disease , Neuroscience , Placebo , Prophylaxis , Eceptor , Espiratory ,